Helicobacter Pylori Infection and the Risk of Myocardial Infarction: Role of Fibrinogen and Its Genetic Control

Summary

The contribution of Helicobacter pylori (HP) infection to the risk of myocardial infarction was evaluated. The role of fibrinogen and its genetic control as a possibile mechanism by which HP may influence myocardial infarction risk was explored in this context. A case-control study was performed in 101 patients with myocardial infarction and in 101 controls.

HP infection was associated with an increased risk of myocardial infarction independently for confounding variables (OR 4.1, CI₉₅: 1.8-9.4). HP infection was significantly associated with higher levels of fibrinogen, both in cases and in controls. Furthermore, there was an additive effect of HP infection and B2 allele of BclI fibrinogen poly-morphism in increasing fibrinogen levels. HP infection showed a stronger effect on the risk of myocardial infarction in B2 allele carriers (OR 7.6, CI₉₅: 1.8-31.6) as compared to subjects carrying the B1B1 genotype (OR 3.3, CI₉₅: 1.2-9.2).

We showed that a previous HP infection is a risk factor for myocardial infarction. An increase in fibrinogen levels is a possible mechanism by which HP may act. Concomitant conditions, like a genetic predisposition in increasing fibrinogen levels, seem to further increase the effect of HP on myocardial infarction risk.

• References

• 1 Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ, Northfield TC. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary artery disease and cardiovascular risk factors. BMJ 1995; 311: 711-4.
• 2 Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-9.
• 3 Lip GH, Wise R, Beevers G. Association of Helicobacter pylori infection with coronary heart disease. Study shows association between Helicobacter pylori infection and hypertension (letter). BMJ 1996; 312: 250-1.
• 4 Morgando A, Sanseverino P, Perotto C, Molino F, Gai V, Ponzetto A. Helicobacter pylori seropositivity in myocardial infarction (letter). Lancet 1995; 345: 1380
• 5 Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 1997; 350: 430-6.
• 6 Murray LJ, Bamford KB, O’Reilly DPJ, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J 1995; 74: 497-501.
• 7 Ernst E, Resch Kl. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of literature. Ann Intern Med 1993; 118: 956-93.
• 8 Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield P, Mendall MA. Fibrinogen: a link between chronic infection and coronary heart disease (letter). Lancet 1994; 343: 1634-5.
• 9 Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-5.
• 10 Iacoviello L, Zito F, Di Castelnuovo A, de Maat M, Kluft C, Donati MB. Contribution of factor VII, fibrinogen and fibrinolytic components to the risk of ischaemic cardiovascular disease: their genetic determinants. Fibrinol Proteol 1998; 12 (05) 259-76.
• 11 Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou J-P, Scarabin P-Y, Bara L, Green F, Cambien F. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996; 93: 440-9.
• 12 Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
• 13 Zito F, Di Castelnuovo A, D'Orazio A, Amore C, Donati MB, Iacoviello L. BclI polymorphism of β-chain fibrinogen gene is associated with the risk of familial myocardial infarction by increasing fibrinogen levels: a case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997; 17: 3489-94.
• 14 Humphries SE, Panahloo A, Montgomery HE, Green F, Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997; 78: 457-61.
• 15 Rose GA, Blackburn H. Cardiovascular Survey Methods. Geneva: World Health Organisation; 1982. 2nd Ed.
• 16 Vitullo F, Marchioli R, Di Mascio R, Cavasinni L, Di Pasquale A, Tognoni G. Family history and socioeconomic factors as predictors of myocardial infarction, unstable angina and stroke in an Italian population. Europ J Epidemiol 1996; 12: 177-85.
• 17 Negrini R, Zanella I, Savio A, Poiesi C, Verardi A, Ghielmi S, Albertini A, Sangaletti O, Lazzaroni M, Bianchi Porro G. Serodiagnosis of Helicobacter pylori-associated gastritis with a monoclonal antibody competitive enzyme-linked immunosorbent assay. Scand J Gastroenterol 1992; 27: 599-605.
• 18 Thomas A, Lamlum H, Humphries S, Green F. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (HaeIII), C/T-148 (HindIII/AluI), T/G+1689 (AvaII), and BclI (β-fibrinogen) and TaqI (α-fibrinogen), and their detection by PCR. Hum Mutat 1994; 3: 79-81.
• 19 Cockburn M, Cox B. The effect of measurement error on the determination of Helicobacter pylori prevalence. Epidemiology 1997; 8: 205-9.
• 20 Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-9.
• 21 Crabtree JE, Shallcross TM, Heatley RV, Wyatt I J. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32: 1473-7.